| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802562501067 | 256250106 | VENTAVIS INH.NE.SOL 10 MCG/ML (20mcg/2ML AMP) BTx 90 AMPS x 2 ML | 1448.90 | 1470.63 | 1625.12 |
| 05/2018 | 2802562501074 | 256250107 | VENTAVIS INH.NE.SOL 10 MCG/ML (20mcg/2ML AMP) BTx3x30 AMPS x 2 ML | 1448.90 | 1470.63 | 1625.12 |
Used for the treatment of pulmonary arterial hypertension.
Iloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) and prostaglandin EP1 receptors. Iloprost constricts the ilium and fundus circular smooth muscle as strongly as prostaglandin E2 (PGE2) itself. Iloprost inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time. All of these properties help to antagonize the pathological changes that take place in the small pulmonary arteries of patients with pulmonary hypertension.
Overdoses can lead to hypotension, headache, flushing, nausea, vomiting, and diarrhea.
Rapidly absorbed with bioavailability of 63%
20-30 minutes
* 0.7 to 0.8 L/kg
* 20 mL/min/kg [Normal subjects]